5I0B
Structure of PAK4
5I0B の概要
| エントリーDOI | 10.2210/pdb5i0b/pdb |
| 分子名称 | Serine/threonine-protein kinase PAK 4, 6-bromo-2-[1-methyl-3-(propan-2-yl)-1H-pyrazol-4-yl]-1H-imidazo[4,5-b]pyridine (2 entities in total) |
| 機能のキーワード | kinase, transferase-transferase inihibitor complex, transferase/transferase inihibitor |
| 由来する生物種 | Homo sapiens (Human) |
| 細胞内の位置 | Cytoplasm : O96013 |
| タンパク質・核酸の鎖数 | 1 |
| 化学式量合計 | 33745.03 |
| 構造登録者 | |
| 主引用文献 | Park, J.K.,Kim, S.,Han, Y.J.,Kim, S.H.,Kang, N.S.,Lee, H.,Park, S.Y. The discovery and the structural basis of an imidazo[4,5-b]pyridine-based p21-activated kinase 4 inhibitor Bioorg. Med. Chem. Lett., 26:2580-2583, 2016 Cited by PubMed Abstract: p21-Activated kinases (PAKs) which belong to the family of ste20 serine/threonine protein kinases regulate cytoskeletal reorganization, cell motility, cell proliferation, and oncogenic transformation which are all related to the cellular functions during cancer induction and metastasis. The fact that PAK mutations are detected in multiple tumor tissues makes PAKs a novel therapeutic drug target. In this study, an imidazo[4,5-b]pyridine-based PAK4 inhibitor, KY-04045 (6-Bromo-2-(3-isopropyl-1-methyl-1H-pyrazol-4-yl)-1H-imidazo[4,5-b]pyridine), was discovered using a virtual site-directed fragment-based drug design and was validated using an inhibition assay. Although PAK4 affinity to KY-04045 seems much weaker than that of the reported PAK4 inhibitors, the location of KY-04045 is clearly defined in the structure of PAK4 co-crystallized with KY-04045. The crystal structure illustrates that the pyrazole and imidazopyridine rings of KY-04045 are sufficient for mediating PAK4 hinge loop interaction. Hence, we believe that KY-04045 can be exploited as a basic building block in designing novel imidazo[4,5-b]pyridine-based PAK4 inhibitors. PubMed: 27117431DOI: 10.1016/j.bmcl.2016.04.037 主引用文献が同じPDBエントリー |
| 実験手法 | X-RAY DIFFRACTION (3.09 Å) |
構造検証レポート
検証レポート(詳細版)
をダウンロード






